Logo image of ZNTL

ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Fundamental Analysis

NASDAQ:ZNTL - Nasdaq - US98943L1070 - Common Stock - Currency: USD

1.51  +0.01 (+0.67%)

After market: 1.46 -0.05 (-3.31%)

Fundamental Rating

3

Overall ZNTL gets a fundamental rating of 3 out of 10. We evaluated ZNTL against 568 industry peers in the Biotechnology industry. ZNTL has a great financial health rating, but its profitability evaluates not so good. ZNTL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZNTL had negative earnings in the past year.
In the past year ZNTL has reported a negative cash flow from operations.
ZNTL had negative earnings in each of the past 5 years.
ZNTL had a negative operating cash flow in each of the past 5 years.
ZNTL Yearly Net Income VS EBIT VS OCF VS FCFZNTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

ZNTL's Return On Assets of -38.54% is in line compared to the rest of the industry. ZNTL outperforms 58.10% of its industry peers.
ZNTL has a better Return On Equity (-49.18%) than 65.32% of its industry peers.
Industry RankSector Rank
ROA -38.54%
ROE -49.18%
ROIC N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ZNTL Yearly ROA, ROE, ROICZNTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZNTL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZNTL Yearly Profit, Operating, Gross MarginsZNTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

7

2. Health

2.1 Basic Checks

ZNTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZNTL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ZNTL has more shares outstanding
There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZNTL Yearly Shares OutstandingZNTL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZNTL Yearly Total Debt VS Total AssetsZNTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.08, we must say that ZNTL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.08, ZNTL is in line with its industry, outperforming 49.47% of the companies in the same industry.
ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.08
ROIC/WACCN/A
WACC10.3%
ZNTL Yearly LT Debt VS Equity VS FCFZNTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

ZNTL has a Current Ratio of 7.32. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.32, ZNTL is in the better half of the industry, outperforming 70.07% of the companies in the same industry.
ZNTL has a Quick Ratio of 7.32. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
ZNTL has a better Quick ratio (7.32) than 70.25% of its industry peers.
Industry RankSector Rank
Current Ratio 7.32
Quick Ratio 7.32
ZNTL Yearly Current Assets VS Current LiabilitesZNTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.86% over the past year.
EPS 1Y (TTM)50.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ZNTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.84% on average per year.
Based on estimates for the next years, ZNTL will show a very strong growth in Revenue. The Revenue will grow by 34.28% on average per year.
EPS Next Y-3.79%
EPS Next 2Y1.43%
EPS Next 3Y5.58%
EPS Next 5Y11.84%
Revenue Next Year-100%
Revenue Next 2Y-27.9%
Revenue Next 3Y-33.97%
Revenue Next 5Y34.28%

3.3 Evolution

ZNTL Yearly Revenue VS EstimatesZNTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ZNTL Yearly EPS VS EstimatesZNTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZNTL. In the last year negative earnings were reported.
Also next year ZNTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZNTL Price Earnings VS Forward Price EarningsZNTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZNTL Per share dataZNTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.43%
EPS Next 3Y5.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZNTL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (4/24/2025, 8:00:02 PM)

After market: 1.46 -0.05 (-3.31%)

1.51

+0.01 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners93.32%
Inst Owner Change0.23%
Ins Owners15%
Ins Owner Change27.02%
Market Cap108.43M
Analysts77.65
Price Target6.4 (323.84%)
Short Float %8.95%
Short Ratio5.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.77%
Min EPS beat(2)13.88%
Max EPS beat(2)39.67%
EPS beat(4)3
Avg EPS beat(4)31.72%
Min EPS beat(4)-44.57%
Max EPS beat(4)117.9%
EPS beat(8)5
Avg EPS beat(8)8.08%
EPS beat(12)7
Avg EPS beat(12)6.88%
EPS beat(16)9
Avg EPS beat(16)4.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-34%
EPS NQ rev (1m)3.77%
EPS NQ rev (3m)18.02%
EPS NY rev (1m)9.2%
EPS NY rev (3m)20.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.61
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-2.28
EYN/A
EPS(NY)-2.37
Fwd EYN/A
FCF(TTM)-2.38
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0.94
BVpS4.7
TBVpS4.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.54%
ROE -49.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.15%
Cap/Sales 0.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.32
Quick Ratio 7.32
Altman-Z -3.08
F-Score5
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)79.15%
Cap/Depr(5y)368.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-3.79%
EPS Next 2Y1.43%
EPS Next 3Y5.58%
EPS Next 5Y11.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-27.9%
Revenue Next 3Y-33.97%
Revenue Next 5Y34.28%
EBIT growth 1Y36.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.13%
EBIT Next 3Y-6.84%
EBIT Next 5YN/A
FCF growth 1Y17.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.79%
OCF growth 3YN/A
OCF growth 5YN/A